1
|
Savchenkova IP, Alekseyenkova SV, Yurov KP. [Mouse embryonic stem cells - a new cellular system for studying the equine infectious anemia virus in vitro and in vivo]. Vopr Virusol 2016; 61:107-111. [PMID: 36494943 DOI: 10.18821/0507-4088-2016-61-3-107-111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2020] [Accepted: 07/12/2020] [Indexed: 12/13/2022]
Abstract
The complexity of the pathogenesis and insufficient knowledge about the slow retroviral infections, which include equine infectious anemia, necessitates finding an adequate laboratory model for the study of the infection process and immunogenesis to create means of prevention and treatment of diseases. Data about strains and cellular tropism of the virus are discussed. It was shown that mouse embryonic stem cells (ESCS) exhibited unique properties and characteristics. In contrast to fibroblasts and other cell types, these cells can be considered as a new cell system for studying EIAV in vitro and in vivo. Under differentiation-inducing conditions they are able to reproduce in vitro embryogenesis cells and form cells of three germ layers. Differentiation of mouse ESCs in the direction of hematopoiesis could contribute new knowledge and understanding of viral tropism EIAV in vitro. ESC can be returned back to the early pre-implantation embryo. Once in the germ cell environment, they participate in the formation of tissues and organs of the developing fetus. Thus, the adaptation of the mouse ESC to the equine EIAV through genetic transformation makes it possible to get closer to the creation of a laboratory model for the study of the in vivo immune response in the lentiviral infection.
Collapse
Affiliation(s)
- I P Savchenkova
- Ya.R. Kovalenko All-Russian Scientific Research Institute of Experimental Veterinary
| | - S V Alekseyenkova
- Ya.R. Kovalenko All-Russian Scientific Research Institute of Experimental Veterinary
| | - K P Yurov
- Ya.R. Kovalenko All-Russian Scientific Research Institute of Experimental Veterinary
| |
Collapse
|
2
|
Farley DC, McCloskey L, Thorne BA, Tareen SU, Nicolai CJ, Campbell DJ, Bannister R, Stewart HJ, Pearson LJ, Moyer BJ, Robbins SH, Zielinski L, Kim T, Radcliffe PA, Mitrophanous KA, Gombotz WR, Miskin JE, Kelley-Clarke B. Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT 2015; 2:15017. [PMID: 26029728 PMCID: PMC4445008 DOI: 10.1038/mtm.2015.17] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 03/04/2015] [Accepted: 03/16/2015] [Indexed: 01/06/2023]
Abstract
It is a current regulatory requirement to demonstrate absence of detectable replication-competent lentivirus (RCL) in lentiviral vector products prior to use in clinical trials. Immune Design previously described an HIV-1-based integration-deficient lentiviral vector for use in cancer immunotherapy (VP02). VP02 is enveloped with E1001, a modified Sindbis virus glycoprotein which targets dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) expressed on dendritic cells in vivo. Vector enveloped with E1001 does not transduce T-cell lines used in standard HIV-1-based RCL assays, making current RCL testing formats unsuitable for testing VP02. We therefore developed a novel assay to test for RCL in clinical lots of VP02. This assay, which utilizes a murine leukemia positive control virus and a 293F cell line expressing the E1001 receptor DC-SIGN, meets a series of evaluation criteria defined in collaboration with US regulatory authorities and demonstrates the ability of the assay format to amplify and detect a hypothetical RCL derived from VP02 vector components. This assay was qualified and used to test six independent GMP production lots of VP02, in which no RCL was detected. We propose that the evaluation criteria used to rationally design this novel method should be considered when developing an RCL assay for any lentiviral vector.
Collapse
Affiliation(s)
- Daniel C Farley
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | - Laura McCloskey
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | | | | | | | | | - Richard Bannister
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | - Hannah J Stewart
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | - Laura Je Pearson
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | | | | | | | - Tae Kim
- Immune Design , Seattle, Washington, USA
| | - Pippa A Radcliffe
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | | | | | - James E Miskin
- Oxford BioMedica (UK) Limited, Windrush Court, Transport Way , Oxford, UK
| | | |
Collapse
|